ACOR - Centrexion Therapeutics Seeks $75 Million In Proposed IPO
Quick Take
Centrexion Therapeutics (CNTX) intends to raise $75 million from the sale of its common stock in an IPO.
The company is advancing a pipeline of next-generation pain treatment candidates.
CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and has reasonable valuation expectations.
Company & Technology
Boston, Massachusetts-based Centrexion was founded in 2013 to develop therapeutics designed to overcome the limitations of current treatment options for chronic pain and to present patients and physicians with better treatment alternatives.
Management is headed by CEO and Director Jeffrey